Advertisement

Warfarin

  • Gregory C. Hadlock
  • Allison E. Burnett
  • Edith A. Nutescu
Chapter

Abstract

Until recently, vitamin K antagonists, such as warfarin, were the only oral anticoagulants available for long-term or extended anticoagulation. Although very effective for prevention and treatment of venous and arterial thromboembolism, warfarin has a narrow therapeutic index, many drug, disease, and dietary interactions, and requires frequent monitoring and dose adjustments (Ageno et al., Chest 141(2 Suppl):e44S–88S, 2012; Holbrook et al., Chest 141(2 Suppl):e152S–84S, 2012; Nutescu et al., J Thromb Thrombolysis 42(2):296–311, 2016; Witt et al., J Thromb Thrombolysis 41:187–205, 2016). These drawbacks have historically resulted in under treatment of patients that warrant anticoagulation therapy (Ogilvie et al., Am J Med. 123(7):638–645.e4, 2010). While direct oral anticoagulants (DOACs) have significantly changed approaches to anticoagulation therapy, are more convenient and are easier to use, warfarin will continue to be a mainstay of therapy for many patients. Thus, clinicians must possess familiarity with this still widely used medication. In this chapter, we will discuss the pharmacology, clinical utility, and practical management aspects that promote optimized safety and efficacy of warfarin therapy.

Keywords

Anticoagulation Atrial fibrillation Cardiac valve Direct oral anticoagulant International normalized ratio Prothrombin complex concentrate Venous thromboembolism Vitamin K Warfarin 

References

  1. 1.
    Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S.CrossRefGoogle Scholar
  2. 2.
    Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S–84S.CrossRefGoogle Scholar
  3. 3.
    Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Erratum to: pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;42(2):296–311.CrossRefGoogle Scholar
  4. 4.
    Witt DM, Clark NP, Kaatz S, Schnurr T, Ansell JE. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41:187–205.CrossRefGoogle Scholar
  5. 5.
    Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123(7):638–645.e4.CrossRefGoogle Scholar
  6. 6.
    Brandjes DP, Heijboer H, Büller HR, de Rijk M, Jagt H, ten Cate JW. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327(21):1485–9.CrossRefGoogle Scholar
  7. 7.
    Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy. 2008;28(9):1084–97.CrossRefGoogle Scholar
  8. 8.
    www.warfarindosing.org. Last accessed 07/12/2017.
  9. 9.
    Kimmel SE. Warfarin pharmacogenomics: current best evidence. J Thromb Haemost. 2015;13(Suppl 1):S266–71.CrossRefGoogle Scholar
  10. 10.
    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin k antagonists*: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6_Suppl):160S–98S.CrossRefGoogle Scholar
  11. 11.
    pi_coumadin.pdf [Internet]. [cited 2017 July 9]. Available from: https://packageinserts.bms.com/pi/pi_coumadin.pdf.
  12. 12.
    Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237–44.CrossRefGoogle Scholar
  13. 13.
    Olesen JB, Sørensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: danish nationwide descriptive data 2011–2013. Europace. 2015;17(2):187–93.CrossRefGoogle Scholar
  14. 14.
    Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.CrossRefGoogle Scholar
  15. 15.
    van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2014;12(3):320–8.CrossRefGoogle Scholar
  16. 16.
    Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–62.CrossRefGoogle Scholar
  17. 17.
    Jacobs V, May HT, Bair TL, Crandall BG, Cutler MJ, Day JD, et al. Long-term population-based cerebral ischemic event and cognitive outcomes of direct oral anticoagulants compared with warfarin among long-term anticoagulated patients for atrial fibrillation. Am J Cardiol. 2016;118(2):210–4.CrossRefGoogle Scholar
  18. 18.
    Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane RD, Shah ND. DIrect comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150(6):1302–12.CrossRefGoogle Scholar
  19. 19.
    Raschi E, Bianchin M, Ageno W, De Ponti R, De Ponti F. Risk–benefit profile of direct-acting oral anticoagulants in established therapeutic indications: an overview of systematic reviews and observational studies. Drug Saf. 2016;39(12):1175–87.CrossRefGoogle Scholar
  20. 20.
    Tamayo S, Frank Peacock W, Patel M, Sicignano N, Hopf KP, Fields LE, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. Clin Cardiol. 2015;38(2):63–8.CrossRefGoogle Scholar
  21. 21.
    Villines TC, Peacock WF. Safety of direct oral anticoagulants: insights from postmarketing studies. Am J Med. 2016;129(11):S41–6.CrossRefGoogle Scholar
  22. 22.
    Xu Y, Schulman S, Dowlatshahi D, Holbrook AM, Simpson CS, Shepherd LE, et al. Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies and outcomes from a multi-center observational study. Chest. 2017;152(1):81–91.  https://doi.org/10.1016/j.chest.2017.02.009.CrossRefPubMedGoogle Scholar
  23. 23.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5(6):e003725.CrossRefGoogle Scholar
  24. 24.
    January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2014;130(23):e199–267.CrossRefGoogle Scholar
  25. 25.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962.CrossRefGoogle Scholar
  26. 26.
    Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: chest guideline and expert panel report. Chest. 2016;149(2):315–52.CrossRefGoogle Scholar
  27. 27.
    Hanon O, Chaussade E, Gueranger P, Gruson E, Bonan S, Gay A. Patient-reported treatment satisfaction with rivaroxaban for stroke prevention in atrial fibrillation. A French observational study, the SAFARI study. PLoS One. 2016;11(12):e0166218.CrossRefGoogle Scholar
  28. 28.
    Toth PP. Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era. Vasc Health Risk Manag. 2016;12:23–34.CrossRefGoogle Scholar
  29. 29.
    Coleman CI, Haas S, Turpie AGG, Kuhls S, Hess S, Evers T, et al. Impact of switching from a vitamin K antagonist to rivaroxaban on satisfaction with anticoagulation therapy: the XANTUS-ACTS substudy. Clin Cardiol. 2016;39(10):565–9.CrossRefGoogle Scholar
  30. 30.
    Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206–32.CrossRefGoogle Scholar
  31. 31.
    Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.CrossRefGoogle Scholar
  32. 32.
    Chai-Adisaksopha C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015;13(11):2012–20.CrossRefGoogle Scholar
  33. 33.
    Garcia DA, Witt DM, Hylek E, Wittkowsky AK, Nutescu EA, Jacobson A, et al. Delivery of optimized anticoagulant therapy: consensus statement from the anticoagulation forum. Ann Pharmacother. 2008;42(7):979–88.CrossRefGoogle Scholar
  34. 34.
    Garcia DA, Schwartz MJ. Warfarin therapy: tips and tools for better control. J Fam Pract. 2011;60(2):70–5.PubMedGoogle Scholar
  35. 35.
    Hospital: 2017 National patient safety goals [Internet]. Available from: http://www.jointcommission.org/hap_2017_npsgs/.
  36. 36.
    Staying Active and Healthy with Blood Thinners” from the Agency for Healthcare Research and Quality (AHRQ). Available at https://www.ahrq.gov/patients-consumers/diagnosis-treatment/treatments/btpills/stayactive.html.
  37. 37.
    Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum. Ann Pharmacother. 2013;47(5):714–24.CrossRefGoogle Scholar
  38. 38.
    Pengo V, Biasiolo A, Pegoraro C. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. Am J Cardiol. 2001;88(10):1214–6.CrossRefGoogle Scholar
  39. 39.
    Tait RC, Sefcick A. A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. Br J Haematol. 1998;101(3):450–4.CrossRefGoogle Scholar
  40. 40.
    Siguret V, Gouin I, Debray M, Perret-Guillaume C, Boddaert J, Mahé I, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med. 2005;118(2):137–42.CrossRefGoogle Scholar
  41. 41.
    Kovacs MJ, Anderson DA, Wells PS. Prospective assessment of a nomogram for the initiation of oral anticoagulation therapy for outpatient treatment of venous thromboembolism. Pathophysiol Haemost Thromb. 2002;32(3):131–3.CrossRefGoogle Scholar
  42. 42.
    Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):257S–98S.CrossRefGoogle Scholar
  43. 43.
    Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med. 1997;126(2):133–6.CrossRefGoogle Scholar
  44. 44.
    Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med. 2000;109(6):481–8.CrossRefGoogle Scholar
  45. 45.
    Rechenmacher SJ, Fang JC. Bridging anticoagulation: Primum Non Nocere. J Am Coll Cardiol. 2015;66(12):1392–403.CrossRefGoogle Scholar
  46. 46.
    Doherty JU, Gluckman TJ, Hucker WJ, Januzzi JL, Ortel TL, Saxonhouse SJ, et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation. J Am Coll Cardiol. 2017;69(7):871–98.CrossRefGoogle Scholar
  47. 47.
    Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630–9.CrossRefGoogle Scholar
  48. 48.
    Clark NP, Witt DM, Davies LE, Saito EM, McCool KH, Douketis JD, et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015;175(7):1163–8.CrossRefGoogle Scholar
  49. 49.
    Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373(9):823–33.CrossRefGoogle Scholar
  50. 50.
    Rose AJ, Allen AL, Minichello T. A call to reduce the use of bridging anticoagulation. Circ Cardiovasc Qual Outcomes. 2016;9(1):64–7.CrossRefGoogle Scholar
  51. 51.
    Nazarian RM, Van Cott EM, Zembowicz A, Duncan LM. Warfarin-induced skin necrosis. J Am Acad Dermatol. 2009;61(2):325–32.CrossRefGoogle Scholar
  52. 52.
    Kozac N, Schattner A. Warfarin-induced skin necrosis. J Gen Intern Med. 2014;29(1):248–9.CrossRefGoogle Scholar
  53. 53.
    Hirschmann JV, Raugi GJ. Blue (or purple) toe syndrome. J Am Acad Dermatol. 2009;60(1):1–20. quiz 21–22.CrossRefGoogle Scholar
  54. 54.
    Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95(3):315–28.CrossRefGoogle Scholar
  55. 55.
    Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med. 2007;120(8):700–5.CrossRefGoogle Scholar
  56. 56.
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–100.CrossRefGoogle Scholar
  57. 57.
    Zhu W, He W, Guo L, Wang X, Hong K. The HAS-BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: a systematic review and meta-analysis. Clin Cardiol. 2015;38(9):555–61.CrossRefGoogle Scholar
  58. 58.
    Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. Hematology Am Soc Hematol Educ Program. 2016;2016(1):620–4.PubMedGoogle Scholar
  59. 59.
    Dentali F, Crowther MA. Management of excessive anticoagulant effect due to vitamin K antagonists. Hematology Am Soc Hematol Educ Program. 2008;2008:266–70.Google Scholar
  60. 60.
    Garcia DA, Crowther MA. Reversal of warfarin. Circulation. 2012;125(23):2944–7.CrossRefGoogle Scholar
  61. 61.
    Garcia DA, Regan S, Crowther M, Hylek EM. The risk of hemorrhage among patients with warfarin-associated coagulopathy. J Am Coll Cardiol. 2006;47(4):804–8.CrossRefGoogle Scholar
  62. 62.
    Crowther MA, Ageno W, Garcia D, Wang L, Witt DM, Clark NP, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Ann Intern Med. 2009;150(5):293–300.CrossRefGoogle Scholar
  63. 63.
    Franchini M, Lippi G. Prothrombin complex concentrates: an update. Blood Transfus. 2010;8(3):149–54.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle N, Iorio A, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016;116(5):879–90.CrossRefGoogle Scholar
  65. 65.
    Brekelmans MPA, van Ginkel K, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis. 2017;44(1):118–29.CrossRefGoogle Scholar
  66. 66.
    Khorsand N, Kooistra HAM, van Hest RM, Veeger NJGM, Meijer K. A systematic review of prothrombin complex concentrate dosing strategies to reverse vitamin K antagonist therapy. Thromb Res. 2015;135(1):9–19.CrossRefGoogle Scholar
  67. 67.
    Logan AC, Goodnough LT. Recombinant factor VIIa: an assessment of evidence regarding its efficacy and safety in the off-label setting. Hematology Am Soc Hematol Educ Program. 2010;2010:153–9.PubMedGoogle Scholar
  68. 68.
    Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med. 2000;160(2):191–6.CrossRefGoogle Scholar
  69. 69.
    Cotrufo M, De Feo M, De Santo LS, Romano G, Della Corte A, Renzulli A, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol. 2002;99(1):35–40.PubMedGoogle Scholar
  70. 70.
    Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33(6):1637–41.CrossRefGoogle Scholar
  71. 71.
    Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-M, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–736S.CrossRefGoogle Scholar
  72. 72.
    Oran B, Lee-Parritz A, Ansell J. Low molecular weight heparin for the prophylaxis of thromboembolism in women with prosthetic mechanical heart valves during pregnancy. Thromb Haemost. 2004;92(4):747–51.PubMedGoogle Scholar
  73. 73.
    De Santo LS, Romano G, Della Corte A, D’Oria V, Nappi G, Giordano S, et al. Mechanical aortic valve replacement in young women planning on pregnancy: maternal and fetal outcomes under low oral anticoagulation, a pilot observational study on a comprehensive pre-operative counseling protocol. J Am Coll Cardiol. 2012;59(12):1110–5.CrossRefGoogle Scholar
  74. 74.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA, et al. AHA/ACC guideline for the management of patients with valvular heart disease. Circulation. 2014;129:CIR.0000000000000031.CrossRefGoogle Scholar
  75. 75.
    European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the task force on the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(24):3147–97.CrossRefGoogle Scholar
  76. 76.
    Shoup J, Carson DS. Anticoagulant use during lactation. J Hum Lact. 1999;15(3):255–7.CrossRefGoogle Scholar
  77. 77.
    Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e737S–801S.CrossRefGoogle Scholar
  78. 78.
    Streif W, Andrew M, Marzinotto V, Massicotte P, Chan AK, Julian JA, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood. 1999;94(9):3007–14.PubMedGoogle Scholar
  79. 79.
    Gillespie MA, Lyle CA, Goldenberg NA. Updates in pediatric venous thromboembolism. Curr Opin Hematol. 2015;22(5):413–9.CrossRefGoogle Scholar
  80. 80.
    von Vajna E, Alam R, So T-Y. Current clinical trials on the use of direct oral anticoagulants in the pediatric population. Cardiol Ther. 2016;5(1):19–41.CrossRefGoogle Scholar
  81. 81.
    Radulescu VC. Anticoagulation therapy in children. Semin Thromb Hemost. 2017.  https://doi.org/10.1055/s-0036-1598004. [Epub ahead of print].

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Gregory C. Hadlock
    • 1
  • Allison E. Burnett
    • 2
  • Edith A. Nutescu
    • 3
  1. 1.Inpatient Pharmacy DepartmentUniversity of New Mexico HospitalAlbuquerqueUSA
  2. 2.University of New Mexico College of PharmacyAlbuquerqueUSA
  3. 3.Department of Pharmacy Systems, Outcomes and Policy, Center for Pharmacoepidemiology and Pharmacoeconomic ResearchThe University of Illinois at Chicago College of PharmacyChicagoUSA

Personalised recommendations